RADIOPHARM THERANOSTICS LIMITED - Announcements

8.82%

3.1¢

Market Cap $73.31M

Healthcare Biotechnology

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics... Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

RAD	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	29/08/25	1.28MB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/25	5.5MB	Share
RAD	RAD receives IND approval from US FDA for Betabart (RV-01)	PRICE SENSITIVE	28/07/25	104.38KB	Share
RAD	RAD Granted US FDA Fast Track for RAD101 Metastases Imaging	PRICE SENSITIVE	11/06/25	108.45KB	Share
RAD	RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202	PRICE SENSITIVE	04/06/25	113.66KB	Share
RAD	RAD Reports Positive Preclinical Lu177-B7H3-mAb Data	PRICE SENSITIVE	02/06/25	265.68KB	Share
RAD	Acceleration of RAD204 Phase 1 dose escalation trial	PRICE SENSITIVE	12/05/25	205.69KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/25	5.63MB	Share
RAD	First patient dosed in Phase IIb imaging for Brain Mets	PRICE SENSITIVE	28/04/25	209.13KB	Share
RAD	New RAD202 data confirms positive tumor uptake	PRICE SENSITIVE	17/03/25	194.91KB	Share
RAD	Half Year Report and Appendix 4D 31 December 2024	PRICE SENSITIVE	28/02/25	2.43MB	Share
RAD	Clinical trial data shows RAD 101 detects Brain Metastases	PRICE SENSITIVE	10/02/25	212.35KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/25	1.49MB	Share
RAD	Lantheus increases shareholding in RAD with A$8m placement	PRICE SENSITIVE	10/01/25	89.1KB	Share
RAD	Strategic Co-Development Partnership with Lantheus for Aus	PRICE SENSITIVE	30/12/24	159.85KB	Share
RAD	RAD 202 receives approval to start Phase 1 therapeutic trial	PRICE SENSITIVE	20/12/24	88.43KB	Share
RAD	Response to ASX Aware Letter	PRICE SENSITIVE	19/12/24	812.59KB	Share
RAD	Completion of preclinical data package for RAD 402	PRICE SENSITIVE	10/12/24	203.1KB	Share
RAD	Approval received to expand RAD204 Phase 1 trial	PRICE SENSITIVE	19/11/24	183.83KB	Share
RAD	RAD 301 shows strong imaging potential in pancreatic cancer	PRICE SENSITIVE	18/11/24	263.54KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/24	1.97MB	Share
RAD	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	30/08/24	3.32MB	Share
RAD	RAD increases ownership in Radiopharm Ventures to 75%	PRICE SENSITIVE	26/08/24	209.68KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	807.73KB	Share
RAD	FDA IND approval for Phase 2b trial in brain metastases	PRICE SENSITIVE	23/07/24	156.63KB	Share
RAD	First patient dosed in Phase 1 therapeutic lung cancer trial	PRICE SENSITIVE	10/07/24	204.12KB	Share
RAD	Reinstatement to Quotation	PRICE SENSITIVE	25/06/24	86KB	Share
RAD	Radiopharm Theranostics completes A$70 million placement	PRICE SENSITIVE	25/06/24	229.95KB	Share
RAD	Suspension from Quotation	PRICE SENSITIVE	24/06/24	512.18KB	Share
RAD	Radiopharm Receives Strategic Investment for up to A$18 mill	PRICE SENSITIVE	20/06/24	206.06KB	Share
RAD	Trading Halt	PRICE SENSITIVE	20/06/24	185.1KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	1.4MB	Share
RAD	Half Yearly Report and Accounts	PRICE SENSITIVE	29/02/24	1.55MB	Share
RAD	Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301	PRICE SENSITIVE	29/02/24	288.52KB	Share
RAD	Pilot Study Validates RAD Terbium-161 Radiotherapeutics	PRICE SENSITIVE	28/02/24	265.19KB	Share
RAD	Radiopharm receives $1.9 M advance on FY24 R&D tax incentive	PRICE SENSITIVE	21/02/24	147.07KB	Share
RAD	RAD secures Share Facility Agreement of up to A$12.5m	PRICE SENSITIVE	06/02/24	308.86KB	Share
RAD	RAD 502 can halt tumour progression and prolong survival	PRICE SENSITIVE	05/02/24	308.3KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	325.51KB	Share
RAD	Placement of Entitlement Offer Shortfall	PRICE SENSITIVE	24/01/24	214.49KB	Share
RAD	2nd Australian site for Nanomab-PDL-1 Phase 1 trial	PRICE SENSITIVE	27/12/23	303.62KB	Share
RAD	Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan	PRICE SENSITIVE	22/12/23	268.51KB	Share
RAD	Completion of Entitlement Offer	PRICE SENSITIVE	08/12/23	162.94KB	Share
RAD	Radiopharm receives $4.85M R&D tax incentive	PRICE SENSITIVE	21/11/23	148.63KB	Share
RAD	Entitlement Offer Documents	PRICE SENSITIVE	08/11/23	5.39MB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	1.47MB	Share
RAD	Entitlement Offer to raise approximately $10 million	PRICE SENSITIVE	31/10/23	228.3KB	Share
RAD	FDA green light for diagnostic Phase 1 pancreatic trial	PRICE SENSITIVE	17/10/23	178.96KB	Share
RAD	RAD receives approval for Phase 1 therapeutic study of NSCLC	PRICE SENSITIVE	09/10/23	134.02KB	Share
RAD	Appendix 4E and FY23 Financial Report	PRICE SENSITIVE	31/08/23	1.79MB	Share
RAD	TerThera Terbium-161 isotope supply agreement expanded	PRICE SENSITIVE	24/08/23	220.37KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	1.33MB	Share
RAD	FDA Pre-IND meeting supports an IND application for RAD 101	PRICE SENSITIVE	29/05/23	132.08KB	Share
RAD	RAD 301 receives FDA Orphan Drug Designation	PRICE SENSITIVE	09/05/23	227.82KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	1.46MB	Share
RAD	Agreement with TerThera to supply Terbium-161 isotope	PRICE SENSITIVE	17/04/23	234.32KB	Share
RAD	Radiopharm to acquire Pharma15 Corporation	PRICE SENSITIVE	03/03/23	152.64KB	Share
RAD	Appendix 4D and Half Year Report	PRICE SENSITIVE	28/02/23	1.56MB	Share
RAD	Radiopharm Theranostics initiates process for Nasdaq listing	PRICE SENSITIVE	14/02/23	209.93KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	2.19MB	Share
RAD	aVb6 Integrin (RAD301) IND approval for Phase 1 trial	PRICE SENSITIVE	30/12/22	140.65KB	Share
RAD	Security Class Reinstatement to Quotation	PRICE SENSITIVE	28/11/22	86.74KB	Share
RAD	Security Class Suspension from Quotation RADO	PRICE SENSITIVE	21/11/22	88.79KB	Share
RAD	Entitlement Offer - Extension of Retail Offer	PRICE SENSITIVE	08/11/22	132.56KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/10/22	2.37MB	Share
RAD	RAD agreement with NorthStar for supply of Actinium-225	PRICE SENSITIVE	26/10/22	165.97KB	Share
RAD	Reinstatement to Quotation	PRICE SENSITIVE	20/10/22	85.7KB	Share
RAD	Successful Completion of Institutional Entitlement Offer	PRICE SENSITIVE	20/10/22	264.11KB	Share
RAD	Entitlement Offer to raise up to $10 million	PRICE SENSITIVE	19/10/22	228.35KB	Share
RAD	Prospectus	PRICE SENSITIVE	19/10/22	1.32MB	Share
RAD	Presentation - Pivalate achieves positive Phase 2 data	PRICE SENSITIVE	18/10/22	516.24KB	Share
RAD	Pivalate achieves positive Phase 2 data in brain mets trial	PRICE SENSITIVE	18/10/22	156.41KB	Share
RAD	Suspension from Official Quotation	PRICE SENSITIVE	17/10/22	124.19KB	Share
RAD	Trading Halt	PRICE SENSITIVE	13/10/22	124.06KB	Share
RAD	FDA grants rare pediatric disease designation for DUNP19	PRICE SENSITIVE	16/09/22	162.46KB	Share
RAD	FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma	PRICE SENSITIVE	09/09/22	158.06KB	Share
RAD	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	31/08/22	265.37KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	2.77MB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	2.39MB	Share
RAD	RAD Licenses UCLA Dual Action Antibody	PRICE SENSITIVE	04/04/22	281.46KB	Share
RAD	LOI with GenesisCare to start first trial in Australia	PRICE SENSITIVE	23/03/22	138.89KB	Share
RAD	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	1.42MB	Share
RAD	Radiopharm and TerraPower sign Actinium 225 agreement	PRICE SENSITIVE	01/02/22	194.54KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/01/22	1.13MB	Share
RAD	RAD acquires IP Ownership of Radiopharmaceutical Nanobodies	PRICE SENSITIVE	24/01/22	165.54KB	Share
RAD	RAD Integrins technology featured in Cancers journal	PRICE SENSITIVE	08/12/21	226.83KB	Share

RAD Appendix 4E and Preliminary Final Report
29/08/25	PRICE SENSITIVE	1.28MB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/07/25	PRICE SENSITIVE	5.5MB	Share
RAD RAD receives IND approval from US FDA for Betabart (RV-01)
28/07/25	PRICE SENSITIVE	104.38KB	Share
RAD RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
11/06/25	PRICE SENSITIVE	108.45KB	Share
RAD RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
04/06/25	PRICE SENSITIVE	113.66KB	Share
RAD RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
02/06/25	PRICE SENSITIVE	265.68KB	Share
RAD Acceleration of RAD204 Phase 1 dose escalation trial
12/05/25	PRICE SENSITIVE	205.69KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/04/25	PRICE SENSITIVE	5.63MB	Share
RAD First patient dosed in Phase IIb imaging for Brain Mets
28/04/25	PRICE SENSITIVE	209.13KB	Share
RAD New RAD202 data confirms positive tumor uptake
17/03/25	PRICE SENSITIVE	194.91KB	Share
RAD Half Year Report and Appendix 4D 31 December 2024
28/02/25	PRICE SENSITIVE	2.43MB	Share
RAD Clinical trial data shows RAD 101 detects Brain Metastases
10/02/25	PRICE SENSITIVE	212.35KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
30/01/25	PRICE SENSITIVE	1.49MB	Share
RAD Lantheus increases shareholding in RAD with A$8m placement
10/01/25	PRICE SENSITIVE	89.1KB	Share
RAD Strategic Co-Development Partnership with Lantheus for Aus
30/12/24	PRICE SENSITIVE	159.85KB	Share
RAD RAD 202 receives approval to start Phase 1 therapeutic trial
20/12/24	PRICE SENSITIVE	88.43KB	Share
RAD Response to ASX Aware Letter
19/12/24	PRICE SENSITIVE	812.59KB	Share
RAD Completion of preclinical data package for RAD 402
10/12/24	PRICE SENSITIVE	203.1KB	Share
RAD Approval received to expand RAD204 Phase 1 trial
19/11/24	PRICE SENSITIVE	183.83KB	Share
RAD RAD 301 shows strong imaging potential in pancreatic cancer
18/11/24	PRICE SENSITIVE	263.54KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/10/24	PRICE SENSITIVE	1.97MB	Share
RAD Appendix 4E and Preliminary Final Report
30/08/24	PRICE SENSITIVE	3.32MB	Share
RAD RAD increases ownership in Radiopharm Ventures to 75%
26/08/24	PRICE SENSITIVE	209.68KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	807.73KB	Share
RAD FDA IND approval for Phase 2b trial in brain metastases
23/07/24	PRICE SENSITIVE	156.63KB	Share
RAD First patient dosed in Phase 1 therapeutic lung cancer trial
10/07/24	PRICE SENSITIVE	204.12KB	Share
RAD Reinstatement to Quotation
25/06/24	PRICE SENSITIVE	86KB	Share
RAD Radiopharm Theranostics completes A$70 million placement
25/06/24	PRICE SENSITIVE	229.95KB	Share
RAD Suspension from Quotation
24/06/24	PRICE SENSITIVE	512.18KB	Share
RAD Radiopharm Receives Strategic Investment for up to A$18 mill
20/06/24	PRICE SENSITIVE	206.06KB	Share
RAD Trading Halt
20/06/24	PRICE SENSITIVE	185.1KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	1.4MB	Share
RAD Half Yearly Report and Accounts
29/02/24	PRICE SENSITIVE	1.55MB	Share
RAD Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301
29/02/24	PRICE SENSITIVE	288.52KB	Share
RAD Pilot Study Validates RAD Terbium-161 Radiotherapeutics
28/02/24	PRICE SENSITIVE	265.19KB	Share
RAD Radiopharm receives $1.9 M advance on FY24 R&D tax incentive
21/02/24	PRICE SENSITIVE	147.07KB	Share
RAD RAD secures Share Facility Agreement of up to A$12.5m
06/02/24	PRICE SENSITIVE	308.86KB	Share
RAD RAD 502 can halt tumour progression and prolong survival
05/02/24	PRICE SENSITIVE	308.3KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	325.51KB	Share
RAD Placement of Entitlement Offer Shortfall
24/01/24	PRICE SENSITIVE	214.49KB	Share
RAD 2nd Australian site for Nanomab-PDL-1 Phase 1 trial
27/12/23	PRICE SENSITIVE	303.62KB	Share
RAD Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan
22/12/23	PRICE SENSITIVE	268.51KB	Share
RAD Completion of Entitlement Offer
08/12/23	PRICE SENSITIVE	162.94KB	Share
RAD Radiopharm receives $4.85M R&D tax incentive
21/11/23	PRICE SENSITIVE	148.63KB	Share
RAD Entitlement Offer Documents
08/11/23	PRICE SENSITIVE	5.39MB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	1.47MB	Share
RAD Entitlement Offer to raise approximately $10 million
31/10/23	PRICE SENSITIVE	228.3KB	Share
RAD FDA green light for diagnostic Phase 1 pancreatic trial
17/10/23	PRICE SENSITIVE	178.96KB	Share
RAD RAD receives approval for Phase 1 therapeutic study of NSCLC
09/10/23	PRICE SENSITIVE	134.02KB	Share
RAD Appendix 4E and FY23 Financial Report
31/08/23	PRICE SENSITIVE	1.79MB	Share
RAD TerThera Terbium-161 isotope supply agreement expanded
24/08/23	PRICE SENSITIVE	220.37KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	1.33MB	Share
RAD FDA Pre-IND meeting supports an IND application for RAD 101
29/05/23	PRICE SENSITIVE	132.08KB	Share
RAD RAD 301 receives FDA Orphan Drug Designation
09/05/23	PRICE SENSITIVE	227.82KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	1.46MB	Share
RAD Agreement with TerThera to supply Terbium-161 isotope
17/04/23	PRICE SENSITIVE	234.32KB	Share
RAD Radiopharm to acquire Pharma15 Corporation
03/03/23	PRICE SENSITIVE	152.64KB	Share
RAD Appendix 4D and Half Year Report
28/02/23	PRICE SENSITIVE	1.56MB	Share
RAD Radiopharm Theranostics initiates process for Nasdaq listing
14/02/23	PRICE SENSITIVE	209.93KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	2.19MB	Share
RAD aVb6 Integrin (RAD301) IND approval for Phase 1 trial
30/12/22	PRICE SENSITIVE	140.65KB	Share
RAD Security Class Reinstatement to Quotation
28/11/22	PRICE SENSITIVE	86.74KB	Share
RAD Security Class Suspension from Quotation RADO
21/11/22	PRICE SENSITIVE	88.79KB	Share
RAD Entitlement Offer - Extension of Retail Offer
08/11/22	PRICE SENSITIVE	132.56KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
26/10/22	PRICE SENSITIVE	2.37MB	Share
RAD RAD agreement with NorthStar for supply of Actinium-225
26/10/22	PRICE SENSITIVE	165.97KB	Share
RAD Reinstatement to Quotation
20/10/22	PRICE SENSITIVE	85.7KB	Share
RAD Successful Completion of Institutional Entitlement Offer
20/10/22	PRICE SENSITIVE	264.11KB	Share
RAD Entitlement Offer to raise up to $10 million
19/10/22	PRICE SENSITIVE	228.35KB	Share
RAD Prospectus
19/10/22	PRICE SENSITIVE	1.32MB	Share
RAD Presentation - Pivalate achieves positive Phase 2 data
18/10/22	PRICE SENSITIVE	516.24KB	Share
RAD Pivalate achieves positive Phase 2 data in brain mets trial
18/10/22	PRICE SENSITIVE	156.41KB	Share
RAD Suspension from Official Quotation
17/10/22	PRICE SENSITIVE	124.19KB	Share
RAD Trading Halt
13/10/22	PRICE SENSITIVE	124.06KB	Share
RAD FDA grants rare pediatric disease designation for DUNP19
16/09/22	PRICE SENSITIVE	162.46KB	Share
RAD FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
09/09/22	PRICE SENSITIVE	158.06KB	Share
RAD Appendix 4E and Preliminary Final Report
31/08/22	PRICE SENSITIVE	265.37KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	2.77MB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	2.39MB	Share
RAD RAD Licenses UCLA Dual Action Antibody
04/04/22	PRICE SENSITIVE	281.46KB	Share
RAD LOI with GenesisCare to start first trial in Australia
23/03/22	PRICE SENSITIVE	138.89KB	Share
RAD Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	1.42MB	Share
RAD Radiopharm and TerraPower sign Actinium 225 agreement
01/02/22	PRICE SENSITIVE	194.54KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
25/01/22	PRICE SENSITIVE	1.13MB	Share
RAD RAD acquires IP Ownership of Radiopharmaceutical Nanobodies
24/01/22	PRICE SENSITIVE	165.54KB	Share
RAD RAD Integrins technology featured in Cancers journal
08/12/21	PRICE SENSITIVE	226.83KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.1¢		Change -0.003(8.82%)		Mkt cap ! $73.31M

Open	High	Low	Value	Volume
3.4¢	3.4¢	3.1¢	$58.95K	1.821M

Buyers (Bids)

No.	Vol.	Price($)
4	783888	3.1¢

Sellers (Offers)

Price($)	Vol.	No.
3.2¢	870662	1

View Market Depth

No.	Vol.	Price($)
4	783888	0.031
3	1230000	0.030
6	505133	0.029
3	649718	0.028
5	1761111	0.027

Price($)	Vol.	No.
0.032	870662	1
0.033	877110	2
0.034	1290328	3
0.035	2373494	10
0.036	1165378	3

Last trade - 16.10pm 19/09/2025 (20 minute delay)

RAD (ASX) Chart

RADIOPHARM THERANOSTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available